Statins Cost-Effective For High-Risk Patients – JAMA Study
This article was originally published in The Tan Sheet
Executive Summary
Statins appear to be cost-effective for high-risk, primary-prevention patients who have an absolute 10-year coronary heart disease-event rate of higher than 20%, according to a meta-analysis in the Nov. 27 Archive of Internal Medicine, a JAMA journal